Clinical use of HIV-1 resistance genotyping.: Predictive factors of poor virological evolution in salvage treatments

被引:0
|
作者
Riera-Jaume, Melcior
Peñaranda-Vera, Maria
Angels Ribas-Blanco, Ma.
Murillas-Angoiti, Javier
Campins, Antoni
Salas-Aparicio, Ana
Leyes-García, María
Pareja-Bezares, Antonio
Pérez, José Luis
Villalonga-Pieras, Concepción
机构
[1] Hosp Univ Son Dureta, Unidad Enfermedades Infecciosas, Med Interna Serv, Palma de Mallorca 07014, Spain
[2] Hosp Son Llatzer, Serv Med Prevent & Epidemiol, Palma de Mallorca, Spain
[3] Hosp Son Dureta, Microbiol Serv, Palma de Mallorca, Spain
来源
关键词
antiretroviral treatment; salvage treatment; HIV infection; antiviral drug resistance; antiviral sensitivity testing;
D O I
10.1016/S0213-005X(06)73767-3
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
OBJECTIVES. To describe the use of genotype resistance testing (GRT) for virological failure in clinical practice, and the long-term clinical and virological evolution in patients for whom it is requested. To identify the predictive factors of virological failure in patients with antiretroviral (ARV) salvage therapy. METHODS. Observational study in HIV-infected patients for whom GRT was requested for virological failure (VF) in the period of 1 October 1999 to 31 December 2001. Logistic regression analysis was used to determine the predictive factors of virological progression. RESULTS. Over the period studied, 196 patients required GRT for VF (15%) among those monitored in specific units. GRT was mainly requested for patients who had been extensively pretreated for a mean of 5 years and with a median of 5 ARV combinations. Half the patients presented 3 or more mutations associated with thymidine analogs (TAMs), mutations associated with non-nucleoside analogs (NNRTIs), and 5 or more mutations associated with protease inhibitors (Pis). In 143 (74%) patients, the RTV regimen was changed on the basis of GRT results. In the intent-to-treat analysis, the percentage of patients with plasma VL < 400 cop/mL at 6,12 and 18 months was 41%,29% and 17%, respectively. In the on-treatment analysis, the results were 50%,48% and 46%, respectively. Mean CD4 lymphocyte increase was 59.74 and 94 cells/mm(3). The variables predicting virological failure (plasma VL > 400 cop/ml) at 12 months were plasma VL > 30,000 cop/mL (OR 6,1.8-19.5) and accumulation of 3 or more TAMs (OR 4.4, 1.3-15) at the start of ARV salvage therapy. CONCLUSION. Even though in clinical practice GRT is requested for patients with various treatment failures, when ART salvage treatment was started, plasma VL was undetectable and immunological response persisted in 40% of patients followed-up for 18 months. The factors best predicting virological evolution were VL and the number of baseline TAMs.
引用
收藏
页码:225 / 231
页数:7
相关论文
共 50 条
  • [21] Virological response and resistance profile in virologically suppressed HIV-1 infected individuals switching to a bictegravir based treatment in clinical practice
    Armenia, D.
    Forbici, F.
    Bertoli, A.
    Berno, G.
    Malagnino, V.
    Gagliardini, R.
    Borghi, V.
    Gennari, W.
    Cicalini, S.
    Buonomini, A.
    Teti, E.
    Latini, A.
    Sarmati, L.
    Mussini, C.
    Andreoni, M.
    Antinori, A.
    Perno, C. F.
    Ceccherini-Silberstein, F.
    Santoro, M. M.
    HIV MEDICINE, 2021, 22 : 26 - 28
  • [22] Sensitivity and specificity of the ViroSeq human immunodeficiency virus type 1 (HIV-1) genotyping system for detection of HIV-1 drug resistance mutations by use of an ABI PRISM 3100 genetic analyzer
    Eshleman, SH
    Crutcher, G
    Petrauskene, O
    Kunstman, K
    Cunningham, SP
    Trevino, C
    Davis, C
    Kennedy, J
    Fairman, J
    Foley, B
    Kop, J
    JOURNAL OF CLINICAL MICROBIOLOGY, 2005, 43 (02) : 813 - 817
  • [23] Comparison of HIV-1 drug-resistance genotyping by ultra-deep sequencing and sanger sequencing using clinical samples
    Trabaud, Mary-Anne
    Icard, Vinca
    Ramiere, Christophe
    Tardy, Jean-Claude
    Scholtes, Caroline
    Andre, Patrice
    JOURNAL OF MEDICAL VIROLOGY, 2017, 89 (11) : 1912 - 1919
  • [24] Development, Validation and Clinical Evaluation of a Low Cost In-House HIV-1 Drug Resistance Genotyping Assay for Indian Patients
    Acharya, Arpan
    Vaniawala, Salil
    Shah, Parth
    Misra, Rabindra Nath
    Wani, Minal
    Mukhopadhyaya, Pratap N.
    PLOS ONE, 2014, 9 (08):
  • [25] Construction, training and clinical validation of an interpretation system for genotypic HIV-1 drug resistance based on fuzzy rules revised by virological outcomes
    De Luca, A
    Vendittelli, M
    Boldini, F
    Di Giambenedetto, S
    Trotta, MP
    Cingolani, A
    Bacarelli, A
    Gori, C
    Perno, CF
    Antinori, A
    Ulivi, G
    ANTIVIRAL THERAPY, 2004, 9 (04) : 583 - 593
  • [26] Clinical Evaluation of an In-House Human Immunodeficiency Virus (HIV) Genotyping Assay for the Detection of Drug Resistance Mutations in HIV-1 Infected Patients in Singapore
    Thew, Kuan Kiat
    Ng, Kah Ying
    Khong, Wei Xin
    Kaur, Palvinder
    Yap, Joe Kwan
    Chua, Arlene
    Tan, Mei Ting
    Koh, Yin Ling
    Thoon, Koh Cheng
    Leo, Yee Sin
    Ng, Oon Tek
    ANNALS ACADEMY OF MEDICINE SINGAPORE, 2012, 41 (12) : 553 - 558
  • [27] Viral evolution in the cell-associated HIV-1 DNA during early ART can lead to drug resistance and virological failure in children
    Gopalan, Bindu Parachalil
    D'Souza, Reena R.
    Rajnala, Niharika
    Arumugam, Karthika
    Dias, Mary
    Ranga, Udaykumar
    Shet, Anita
    JOURNAL OF MEDICAL VIROLOGY, 2019, 91 (06) : 1036 - 1047
  • [28] Treatment history adds little or no predictive value to HIV-1 genotypic resistance interpretation during highly active antiretroviral therapy failure for subsequent virological outcome: different value according to interpretation system and salvage treatment
    De Luca, A
    Giambenedetto, S
    Baldini, F
    Rizzo, MG
    Cingolani, A
    Trotta, MP
    Giannella, S
    Narciso, P
    Perno, CF
    Ulivi, G
    Antinori, A
    ANTIVIRAL THERAPY, 2002, 7 : S100 - S100
  • [29] Long-term evolution of immunological and virological parameters in patients undergoing treatments for HIV-1 infection at the Day Hospital of Bobo-Dioulasso, Burkina Faso
    Samba, Jessica Julie Chantal
    Sawadogo, Yacouba
    Sombie, Herman Karim
    Kafando, Herve
    Zougmore, Wendinmi Arnaud Marie Joseph
    Damolga, Maxime
    Ouattara, Cheick Ahmed
    Poda, Armel
    Ouedraogo, Abdoul-Salam
    PAN AFRICAN MEDICAL JOURNAL, 2023, 44
  • [30] Efficacy, safety and predictive factors of virological success of a boosted amprenavir-based salvage regimen in heavily antiretroviral-experienced HIV-1-infected patients
    Clevenbergh, P
    Boulmé, R
    Kirstetter, M
    Dellamonica, P
    HIV MEDICINE, 2004, 5 (04) : 284 - 288